ProPhase Labs, Inc. (PRPH) stock declined over -4.41%, trading at $0.33 on NASDAQ, down from the previous close of $0.34. The stock opened at $0.29, fluctuating between $0.28 and $0.40 in the recent session.
ProPhase Labs, Inc. engages in the research, development, manufacture, distribution, marketing, and sale of over the counter (OTC) consumer healthcare products and dietary supplements in the United States. The company operates in two segments, Diagnostic Services and Consumer Products. It offers a range of OTC dietary supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster. The company also provides contract manufacturing services, such as product development, pre-commercialization, production, warehousing, and distribution; SARS-CoV-2 (COVID-19) and COVID-19 viral mutation polymerase chain reaction tests through saliva and nasal swab methods; and other respiratory pathogen panel molecular testing services, as well as personal genomics products and services. It serves national chain drug, internet-based, and various regional retailers. The company was formerly known as The Quigley Corporation. ProPhase Labs, Inc. was founded in 1989 and is headquartered in Garden City, New York.
Employees | 113 |
Beta | -0.1 |
Sales or Revenue | $44.38M |
5Y Sales Change% | 1.239% |
Fiscal Year Ends | December |
Sector | Healthcare |
Industry | Drug Manufacturers - Specialty & Generic |
ProPhase Labs, Inc. (NASDAQ: PRPH) stock price is $0.33 in the last trading session. During the trading session, PRPH stock reached the peak price of $0.40 while $0.28 was the lowest point it dropped to. The percentage change in PRPH stock occurred in the recent session was -4.41% while the dollar amount for the price change in PRPH stock was -$0.02.
The NASDAQ listed PRPH is part of Drug Manufacturers - Specialty & Generic industry that operates in the broader Healthcare sector. ProPhase Labs, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.
Mr. Jason Karkus
Pres of ProPhase Diagnostics
Mr. Ted William Karkus
Chairman & Chief Executive Officer
Ms. Monica Brady
Chief Accounting Officer
Mr. Billy Joe White
Consultant
Mr. Sergio Miralles
Executive Vice President & Chief Information Officer of ProPhase Diagnostics
Mr. Kamal Obbad
Senior Vice President and Director of Sales & Marketing - Nebula Genomics
Mr. Robert A. Morse Jr.
Chief Financial Officer, Principal Financial Officer & Principal Accounting Officer
Mr. Sam A. Beeler
Chief Strategy Officer of Nebula Genomics
Ms. Alice Lioi
EVice President & Chief Operating Officer of ProPhase Diagnostics and ProPhase BioPharma
Mr. Dennis Grishin
Chief Scientific Officer of Nebula Genomics
PRPH's closing price is 47.73% higher than its 52-week low of $0.22 where as its distance from 52-week high of $7.48 is -95.66%.
Number of PRPH employees currently stands at 113.
Official Website of PRPH is: https://www.prophaselabs.com
PRPH could be contacted at phone 215 345 0919 and can also be accessed through its website. PRPH operates from 711 Stewart Avenue, Garden City, NY 11530, United States.
PRPH stock volume for the day was 12.64M shares. The average number of PRPH shares traded daily for last 3 months was 3.28M.
The market value of PRPH currently stands at $9.71M with its latest stock price at $0.33 and 29.87M of its shares outstanding.
© 2025 Stocks Telegraph All rights reserved.
Most stock quote data provided by financialmodelingprep.com